The science surrounding brain injury treatment and recovery is advancing at such a rapid pace that this forum for collaboration is rich with opportunity to identify efficiencies and solutions that improve outcomes for brain injury survivors.
MINNEAPOLIS (PRWEB) March 19, 2018
Arrowhead Publishers has released the agenda for the 8th annual Traumatic Brain Injury (TBI) Conference, announcing more than 25 expert speakers and 30 presentations and panel sessions, addressing several areas of focus surrounding emerging neuroscience, TBI treatment, and novel approaches under exploration.
Focus areas will include:
- TBI Clinical Trials
- Neurodegeneration and TBI
- CTE Pathobiology
- Outcomes Research
- Blood Biomarkers
- Point of Care Diagnostics
- Preclinical Research
The TBI Conference brings together physicians, nurses, neurosurgeons, scientists, and drug-diagnostic developers from all over the world to join in networking and learning. The event will return to Washington, D.C., May 16-17 at the Westin Arlington Gateway. It provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made toward better diagnosis, treatment and long-term care for TBI survivors. The conference has become a forum for leaders and high-level executives from the pharmaceutical, biotech, academic and government communities to discuss new avenues of research in the field of traumatic brain injury, and the latest advances in the field.
Speakers for the conference include:
- Frank Baas, MD, Ph.D., Complement Pharma, Leiden University Medical Center
- Peter Bergold, Ph.D., SUNY Downstate Medical Center
- David Brody, MD, Ph.D., Uniformed Services University of the Health Sciences
- Akiva Cohen, Ph.D., University of Pennsylvania
- Ramon Diaz-Arrastia, MD, Ph.D., Penn Medicine, University of Pennsylvania
- Sam Gandy, MD, Ph.D., Icahn School of Medicine at Mount Sinai
- Raquel Gardner, MD, UCSF School of Medicine
- Jamshid Ghajar, MD, Ph.D., Stanford University School of Medicine
- Lee Goldstein, MD, Ph.D., Boston University Alzheimer’s Disease Center
- Magnus Hansson, MD, Ph.D., NeuroVive Pharmaceutical
- Melissa Hunfalvay, Ph.D., RightEye
- Doug Jeffery, Ph.D., US Food and Drug Administration
- Andreas Jeromin, Ph.D., Quanterix
- Bruce Lamb, Ph.D., Indiana University School of Medicine
- Dianne Langford, Ph.D., Temple University
- Mark Lovell, Ph.D., ImPACT Applications
- Lynn McGrath Jr., MD, University of Washington
- W. Frank Peacock, IV, MD, FACEP, Baylor College of Medicine
- Leslie Prichep, Ph.D., Brainscope, NYU School of Medicine
- Susanna Rosi, Ph.D., Weill Institute for Neuroscience, University of California San Francisco
- Akhil Saklecha, MD, MBA, Artiman Ventures
- Gary Small, MD, UCLA Longevity Center, UCLA
- Uzma Samadani, MD, Ph.D., University of Minnesota, Minneapolis VA Medical Center, Hennepin County Medical Center
- Kert Viele, Ph.D., Berry Consultants
- Evan Unger, MD, NuVox, University of Arizona
- Cheryl Wellington, Ph.D., University of British Columbia
- Ross Zafonte, DO, Harvard Medical School, Spaulding Rehabilitation Hospital
“We’re proud to have the brightest minds in TBI research presenting their recent findings and sharing in panel discussions,” said John Waslif, Managing Director of Arrowhead Publishers. “The science surrounding brain injury treatment and recovery is advancing at such a rapid pace that this forum for collaboration is rich with opportunity to identify efficiencies and solutions that improve outcomes for brain injury survivors.”
Traumatic Brain Injury is a major cause of death and disability globally, and is considered a serious health problem. In the United States, an estimated 1.7 million people sustain a traumatic brain injury each year, and more than 30 percent of all reported injury-related deaths list TBI as a contributing factor. Mild traumatic brain injury is the most common combat-related injury, and -- along with spinal cord injury -- TBI accounts for nearly 25 percent of combat casualties.
Treatment of TBI, and especially acute TBI is still a major unmet medical need. Therapies that prove an ability to limit the damage done to the brain and improve clinical outcomes of patients of TBI will have a major impact on the global pharmaceutical market.
Although past clinical trials for new therapies have ended in failure, emerging science has renewed interest across the medical and pharmaceutical fields. Recent initiatives from both the U.S. Congress and Department of Defense to improve treatment options for TBI patients are encouraging indications that the time has come for a rethinking of the potential for pharmaceutical management of conditions caused by traumatic brain injury.
There are several ways to participate in the conference and engage TBI experts and leaders:
View the Agenda: http://www.tbiconference.com/home/2018agenda
Request a Brochure: http://www.tbiconference.com/home/brochure
Register to Attend: http://www.tbiconference.com
Submit a Poster: http://www.tbiconference.com/home/poster-session
Explore Sponsorship and Exhibit Opportunities: http://www.tbiconference.com/home/sponsor-exhibit
Join the Mailing List: http://www.tbiconference.com/home/mailing-list
Keep up-to-date on conference news by following @tbiconference on Twitter and joining The Traumatic Brain Injury R&D Network on LinkedIn.
Arrowhead Publishers brings life sciences industry professionals together to help move research forward through learning, networking and professional growth. Arrowhead focuses on offering thoughtfully curated speakers, new research industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Arrowhead conferences cover clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals.